HilleVax Ownership | Who Owns HilleVax?
HilleVax Ownership Summary
HilleVax is owned by 82.78% institutional investors, 17.09% insiders, and 0.14% retail investors. Frazier life sciences management is the largest institutional shareholder, holding 21.19% of HLVX shares. Franklin Biotechnology Discv A(acc)USD is the top mutual fund, with 2.52% of its assets in HilleVax shares.
HLVX Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | HilleVax | 82.78% | 17.09% | 0.14% |
Sector | Healthcare Stocks | 488.17% | 11.08% | -399.26% |
Industry | Biotech Stocks | 306.59% | 11.10% | -217.69% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Frazier life sciences management | 10.62M | 21.19% | $21.13M |
Takeda pharmaceutical | 6.72M | 13.42% | $13.38M |
Tang capital management | 4.92M | 9.82% | $9.79M |
Blackrock | 2.09M | 4.31% | $30.23M |
Franklin resources | 1.96M | 3.96% | $4.05M |
Deerfield management company, l.p. (series c) | 1.88M | 3.76% | $3.75M |
Carlyle group | 1.84M | 3.67% | $3.59M |
Vanguard group | 1.61M | 3.25% | $3.32M |
Balyasny asset management | 976.30K | 1.95% | $1.94M |
Stepstone group lp | 826.57K | 1.65% | $1.64M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Takeda pharmaceutical | 6.72M | 68.43% | $13.38M |
Stepstone group lp | 826.57K | 3.26% | $1.64M |
Qiming u.s. ventures management | 372.62K | 1.51% | $771.31K |
Frazier life sciences management | 10.62M | 0.84% | $21.13M |
Tang capital management | 4.92M | 0.49% | $9.79M |
Stonepine capital management | 226.01K | 0.44% | $449.76K |
Trium capital llp | 395.19K | 0.20% | $786.42K |
Samsara biocapital | 399.64K | 0.16% | $795.28K |
Bml capital management | 91.91K | 0.14% | $182.91K |
Carlyle group | 1.84M | 0.07% | $3.59M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Goldman sachs group | 699.35K | 0.00% | 453.02K |
Blackrock | 2.09M | 0.00% | 290.33K |
Rbf capital | 200.00K | 0.02% | 200.00K |
Jpmorgan chase | 207.15K | - | 193.12K |
Acadian asset management | 308.60K | 0.00% | 142.82K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
T. rowe price investment management | - | - | -3.48M |
Vr adviser | - | - | -2.08M |
Deep track capital, lp | - | - | -1.83M |
Blackrock funding, inc. /de | 387.53K | - | -1.71M |
Janus henderson group | - | - | -1.12M |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Rbf capital | 200.00K | 0.02% | 200.00K | $398.00K |
Y-intercept (hong kong) | 109.15K | 0.01% | 109.15K | $217.21K |
Militia capital partners, lp | 71.61K | 0.07% | 71.61K | $142.50K |
Qube research | 49.96K | 0.00% | 49.96K | $99.43K |
Quadrature capital | 30.94K | 0.00% | 30.94K | $61.58K |
Sold Out
Holder | Change |
---|---|
Nelson, van denburg & campbell wealth management group | -4.00 |
Quarry lp | -61.00 |
Legacy advisors | -103.00 |
Coldstream capital management | -187.00 |
Parkside financial bank & trust | -285.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Jun 30, 2025 | 73 | -9.88% | 41,482,997 | -1.61% | 82 | 1.16% | 32 | 3.23% | 30 | - |
Mar 31, 2025 | 4 | -94.74% | 13,054,137 | -69.53% | 26 | 0.35% | - | -100.00% | 1 | -93.33% |
Dec 31, 2024 | 45 | -43.04% | 18,234,599 | -56.32% | 36 | 0.52% | 26 | -46.94% | 7 | -61.11% |
Sep 30, 2024 | 78 | -13.33% | 35,023,214 | -9.66% | 70 | 1.11% | 49 | -24.62% | 18 | 50.00% |
Jun 30, 2024 | 90 | 13.92% | 38,767,553 | 4.27% | 79 | 1.31% | 65 | 62.50% | 12 | -47.83% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Franklin Biotechnology Discv A(acc)USD | 1.26M | 2.52% | - |
T. Rowe Price US Small-Cap Core Equity | 806.64K | 1.62% | 173.56K |
iShares Russell 2000 ETF | 778.04K | 1.55% | - |
Vanguard Total Stock Mkt Idx Inv | 741.84K | 1.48% | -16.21K |
Franklin Biotechnology Discovery A | 691.36K | 1.38% | - |
T. Rowe Price U.S. SC Value Eq Tr-Z | 439.91K | 0.88% | 3.33K |
T. Rowe Price U.S. SC Core Eq Tr-Z | 394.48K | 0.79% | 89.26K |
Fidelity Small Cap Index | 301.08K | 0.60% | - |
Xtrackers S&P 500 Swap ETF 1C | 298.90K | 0.60% | - |
Vanguard Institutional Extnd Mkt Idx Tr | 266.40K | 0.53% | -121.39K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Feb 11, 2025 | HERSHBERG ROBERT | See Remarks | Sell | $21.00K |
Feb 04, 2025 | HERSHBERG ROBERT | See Remarks | Sell | $27.66K |
Feb 11, 2025 | Maltbie Shane | Chief Financial Officer | Sell | $7.66K |
Feb 04, 2025 | Maltbie Shane | Chief Financial Officer | Sell | $7.46K |
May 22, 2024 | Kohli Aditya | - | Sell | $88.37K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q2 | - | - |
2025 Q1 | - | 4 |
2024 Q2 | 1 | 9 |
2024 Q1 | 1 | 14 |
2023 Q4 | - | 5 |
HLVX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools